Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients’ Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine

Table 3

Cellular and humoral immune responses to the vaccine antigens.

	PPV + JTT	PPV alone	𝑃 value
Cellular immune responses to the vaccine antigens*
Before vaccination	2/27 (7.4%)	4/28 (14.3%)	0.669
After vaccination	5/22 (22.7%)	11/26 (42.3%)	0.260
Humoral immune responses to the vaccine antigens^†
Augmented	10/23 (43.5%)	10/27 (37.0%)	0.643

∗Antigen-specific T-cell responses were evaluated by IFN-𝛾 ELISPOT assay before and after the first cycle of vaccination.
^†Antigen-specific IgG titers in plasma were evaluated before and after the first cycle of vaccination. If peptide-specific IgG titers in the postvaccination plasma were more than 2-fold higher than those in the prevaccination plasma in at least one of the vaccine peptides, the antigen-specific humoral immune response was considered to be augmented.